Pretargeting for imaging and therapy in oncological nuclear medicine View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-06-06

AUTHORS

Clément Bailly, Caroline Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, Jacques Barbet

ABSTRACT

BackgroundOncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles.ResultsWe have reviewed the pretargeting approaches proposed over the years, discussing their suitability for imaging, particularly PET imaging, and therapy, as well as their limitations. The reviewed pretargeting modalities are the avidin-biotin system, bispecific anti-tumour x anti-hapten antibodies and bivalent haptens, antibody-oligonucleotide conjugates and radiolabelled complementary oligonucleotides, and approaches using click chemistry. Finally, we discuss recent developments, such as the use of small binding proteins for pretargeting that may offer new perspectives to cancer pretargeting.ConclusionsWhile pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives. More... »

PAGES

6

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s41181-017-0026-8

DOI

http://dx.doi.org/10.1186/s41181-017-0026-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085900845

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29503847


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, CHU de Nantes, Nantes, France", 
            "Centre de Recherche en Canc\u00e9rologie Nantes/Angers (CRCNA), Nantes, France", 
            "6299 CNRS, Nantes, France", 
            "UMR892 Inserm, Nantes, France", 
            "Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailly", 
        "givenName": "Cl\u00e9ment", 
        "id": "sg:person.0665453076.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, CHU de Nantes, Nantes, France", 
            "Centre de Recherche en Canc\u00e9rologie Nantes/Angers (CRCNA), Nantes, France", 
            "6299 CNRS, Nantes, France", 
            "UMR892 Inserm, Nantes, France", 
            "Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bodet-Milin", 
        "givenName": "Caroline", 
        "id": "sg:person.01212260416.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, Institut de Canc\u00e9rologie de l\u2019Ouest, Saint-Herblain, France", 
            "Centre de Recherche en Canc\u00e9rologie Nantes/Angers (CRCNA), Nantes, France", 
            "6299 CNRS, Nantes, France", 
            "UMR892 Inserm, Nantes, France", 
            "Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rousseau", 
        "givenName": "Caroline", 
        "id": "sg:person.01240530667.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, CHU de Nantes, Nantes, France", 
            "Centre de Recherche en Canc\u00e9rologie Nantes/Angers (CRCNA), Nantes, France", 
            "6299 CNRS, Nantes, France", 
            "UMR892 Inserm, Nantes, France", 
            "Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre-Chauvet", 
        "givenName": "Alain", 
        "id": "sg:person.01334456404.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334456404.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Nantes, Nantes, France", 
          "id": "http://www.grid.ac/institutes/grid.4817.a", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, CHU de Nantes, Nantes, France", 
            "Service de M\u00e9decine Nucl\u00e9aire, Institut de Canc\u00e9rologie de l\u2019Ouest, Saint-Herblain, France", 
            "Centre de Recherche en Canc\u00e9rologie Nantes/Angers (CRCNA), Nantes, France", 
            "6299 CNRS, Nantes, France", 
            "UMR892 Inserm, Nantes, France", 
            "Universit\u00e9 de Nantes, Nantes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kraeber-Bod\u00e9r\u00e9", 
        "givenName": "Fran\u00e7oise", 
        "id": "sg:person.0653324404.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GIP Arronax, 1, rue Arronax, 44187, Saint-Herblain cedex, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Universit\u00e9 de Nantes, Nantes, France", 
            "GIP Arronax, 1, rue Arronax, 44187, Saint-Herblain cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barbet", 
        "givenName": "Jacques", 
        "id": "sg:person.01001654663.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00259-011-1903-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042179776", 
          "https://doi.org/10.1007/s00259-011-1903-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2403751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011048164", 
          "https://doi.org/10.1038/sj.leu.2403751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-014-2742-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031939770", 
          "https://doi.org/10.1007/s00259-014-2742-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrendo.2013.246", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047670596", 
          "https://doi.org/10.1038/nrendo.2013.246"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2013.376", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018150595", 
          "https://doi.org/10.1038/bjc.2013.376"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-06-06", 
    "datePublishedReg": "2017-06-06", 
    "description": "BackgroundOncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30\u00a0years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles.ResultsWe have reviewed the pretargeting approaches proposed over the years, discussing their suitability for imaging, particularly PET imaging, and therapy, as well as their limitations. The reviewed pretargeting modalities are\u00a0the avidin-biotin system, bispecific anti-tumour x anti-hapten antibodies and bivalent haptens, antibody-oligonucleotide conjugates and radiolabelled complementary oligonucleotides, and approaches using click chemistry. Finally, we discuss recent developments, such as the use of small binding proteins for pretargeting that may offer new perspectives to cancer pretargeting.ConclusionsWhile pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s41181-017-0026-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1157056", 
        "issn": [
          "2365-421X"
        ], 
        "name": "EJNMMI Radiopharmacy and Chemistry", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "clinical development program", 
      "anti-hapten antibodies", 
      "clinical trials", 
      "preclinical models", 
      "precision medicine perspective", 
      "clinical proof", 
      "medicine perspective", 
      "therapy", 
      "PET imaging", 
      "clinical reality", 
      "pretargeting approach", 
      "pretargeting", 
      "bivalent hapten", 
      "market approval", 
      "nuclear medicine", 
      "imaging", 
      "antibody-oligonucleotide conjugates", 
      "years", 
      "trials", 
      "antibodies", 
      "ResultsWe", 
      "promising results", 
      "modalities", 
      "positron emitters", 
      "approval", 
      "beta", 
      "medicine", 
      "biotin system", 
      "hapten", 
      "PET", 
      "conjugates", 
      "protein", 
      "use", 
      "program", 
      "promise", 
      "new perspective", 
      "development", 
      "theranostics", 
      "development programs", 
      "recent developments", 
      "results", 
      "limitations", 
      "radionuclides", 
      "approach", 
      "oligonucleotide", 
      "perspective", 
      "model", 
      "different ways", 
      "system", 
      "suitability", 
      "proof", 
      "alpha particles", 
      "way", 
      "click chemistry", 
      "principles", 
      "complementary oligonucleotides", 
      "reality", 
      "particles", 
      "emitters", 
      "chemistry"
    ], 
    "name": "Pretargeting for imaging and therapy in oncological nuclear medicine", 
    "pagination": "6", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085900845"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s41181-017-0026-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29503847"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s41181-017-0026-8", 
      "https://app.dimensions.ai/details/publication/pub.1085900845"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_737.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s41181-017-0026-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s41181-017-0026-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s41181-017-0026-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s41181-017-0026-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s41181-017-0026-8'


 

This table displays all metadata directly associated to this object as RDF triples.

184 TRIPLES      21 PREDICATES      90 URIs      77 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s41181-017-0026-8 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nc7799faae9424db7a581ef014fb3d534
4 schema:citation sg:pub.10.1007/s00259-011-1903-0
5 sg:pub.10.1007/s00259-014-2742-6
6 sg:pub.10.1038/bjc.2013.376
7 sg:pub.10.1038/nrendo.2013.246
8 sg:pub.10.1038/sj.leu.2403751
9 schema:datePublished 2017-06-06
10 schema:datePublishedReg 2017-06-06
11 schema:description BackgroundOncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles.ResultsWe have reviewed the pretargeting approaches proposed over the years, discussing their suitability for imaging, particularly PET imaging, and therapy, as well as their limitations. The reviewed pretargeting modalities are the avidin-biotin system, bispecific anti-tumour x anti-hapten antibodies and bivalent haptens, antibody-oligonucleotide conjugates and radiolabelled complementary oligonucleotides, and approaches using click chemistry. Finally, we discuss recent developments, such as the use of small binding proteins for pretargeting that may offer new perspectives to cancer pretargeting.ConclusionsWhile pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives.
12 schema:genre article
13 schema:isAccessibleForFree true
14 schema:isPartOf N37b9db0a317b4d97bfc18c8733aa0c30
15 Nf5f037045f6f4cb0af0cf2d21e4ffaa0
16 sg:journal.1157056
17 schema:keywords PET
18 PET imaging
19 ResultsWe
20 alpha particles
21 anti-hapten antibodies
22 antibodies
23 antibody-oligonucleotide conjugates
24 approach
25 approval
26 beta
27 biotin system
28 bivalent hapten
29 chemistry
30 click chemistry
31 clinical development program
32 clinical proof
33 clinical reality
34 clinical trials
35 complementary oligonucleotides
36 conjugates
37 development
38 development programs
39 different ways
40 emitters
41 hapten
42 imaging
43 limitations
44 market approval
45 medicine
46 medicine perspective
47 modalities
48 model
49 new perspective
50 nuclear medicine
51 oligonucleotide
52 particles
53 perspective
54 positron emitters
55 precision medicine perspective
56 preclinical models
57 pretargeting
58 pretargeting approach
59 principles
60 program
61 promise
62 promising results
63 proof
64 protein
65 radionuclides
66 reality
67 recent developments
68 results
69 suitability
70 system
71 theranostics
72 therapy
73 trials
74 use
75 way
76 years
77 schema:name Pretargeting for imaging and therapy in oncological nuclear medicine
78 schema:pagination 6
79 schema:productId N7314daf98dbf48bbbed13272a4f08558
80 Naaa7ebb0990447d1bace3184b9424ba4
81 Nebaecd56a6624c8db308db7b4aaf4310
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085900845
83 https://doi.org/10.1186/s41181-017-0026-8
84 schema:sdDatePublished 2022-11-24T21:02
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Nf32c3f8f24b34b88965465f760aa8085
87 schema:url https://doi.org/10.1186/s41181-017-0026-8
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N172b2530be3d491ca51403733060edc6 rdf:first sg:person.01212260416.00
92 rdf:rest N90aa492b1fd145d7a24145045038041e
93 N37b9db0a317b4d97bfc18c8733aa0c30 schema:issueNumber 1
94 rdf:type schema:PublicationIssue
95 N6c97b74c12bf4fbcbd82aca735b1d591 rdf:first sg:person.01334456404.06
96 rdf:rest Nc73fb547d08942b5843dcd216e2a564a
97 N7314daf98dbf48bbbed13272a4f08558 schema:name dimensions_id
98 schema:value pub.1085900845
99 rdf:type schema:PropertyValue
100 N90aa492b1fd145d7a24145045038041e rdf:first sg:person.01240530667.47
101 rdf:rest N6c97b74c12bf4fbcbd82aca735b1d591
102 Naaa7ebb0990447d1bace3184b9424ba4 schema:name doi
103 schema:value 10.1186/s41181-017-0026-8
104 rdf:type schema:PropertyValue
105 Nc673e8ce27944fd38906b1610bd9b0f8 rdf:first sg:person.01001654663.28
106 rdf:rest rdf:nil
107 Nc73fb547d08942b5843dcd216e2a564a rdf:first sg:person.0653324404.03
108 rdf:rest Nc673e8ce27944fd38906b1610bd9b0f8
109 Nc7799faae9424db7a581ef014fb3d534 rdf:first sg:person.0665453076.40
110 rdf:rest N172b2530be3d491ca51403733060edc6
111 Nebaecd56a6624c8db308db7b4aaf4310 schema:name pubmed_id
112 schema:value 29503847
113 rdf:type schema:PropertyValue
114 Nf32c3f8f24b34b88965465f760aa8085 schema:name Springer Nature - SN SciGraph project
115 rdf:type schema:Organization
116 Nf5f037045f6f4cb0af0cf2d21e4ffaa0 schema:volumeNumber 2
117 rdf:type schema:PublicationVolume
118 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
119 schema:name Medical and Health Sciences
120 rdf:type schema:DefinedTerm
121 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
122 schema:name Oncology and Carcinogenesis
123 rdf:type schema:DefinedTerm
124 sg:journal.1157056 schema:issn 2365-421X
125 schema:name EJNMMI Radiopharmacy and Chemistry
126 schema:publisher Springer Nature
127 rdf:type schema:Periodical
128 sg:person.01001654663.28 schema:affiliation grid-institutes:None
129 schema:familyName Barbet
130 schema:givenName Jacques
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28
132 rdf:type schema:Person
133 sg:person.01212260416.00 schema:affiliation grid-institutes:grid.4817.a
134 schema:familyName Bodet-Milin
135 schema:givenName Caroline
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212260416.00
137 rdf:type schema:Person
138 sg:person.01240530667.47 schema:affiliation grid-institutes:grid.4817.a
139 schema:familyName Rousseau
140 schema:givenName Caroline
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
142 rdf:type schema:Person
143 sg:person.01334456404.06 schema:affiliation grid-institutes:grid.4817.a
144 schema:familyName Faivre-Chauvet
145 schema:givenName Alain
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334456404.06
147 rdf:type schema:Person
148 sg:person.0653324404.03 schema:affiliation grid-institutes:grid.4817.a
149 schema:familyName Kraeber-Bodéré
150 schema:givenName Françoise
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03
152 rdf:type schema:Person
153 sg:person.0665453076.40 schema:affiliation grid-institutes:grid.4817.a
154 schema:familyName Bailly
155 schema:givenName Clément
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665453076.40
157 rdf:type schema:Person
158 sg:pub.10.1007/s00259-011-1903-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042179776
159 https://doi.org/10.1007/s00259-011-1903-0
160 rdf:type schema:CreativeWork
161 sg:pub.10.1007/s00259-014-2742-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031939770
162 https://doi.org/10.1007/s00259-014-2742-6
163 rdf:type schema:CreativeWork
164 sg:pub.10.1038/bjc.2013.376 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018150595
165 https://doi.org/10.1038/bjc.2013.376
166 rdf:type schema:CreativeWork
167 sg:pub.10.1038/nrendo.2013.246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047670596
168 https://doi.org/10.1038/nrendo.2013.246
169 rdf:type schema:CreativeWork
170 sg:pub.10.1038/sj.leu.2403751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011048164
171 https://doi.org/10.1038/sj.leu.2403751
172 rdf:type schema:CreativeWork
173 grid-institutes:None schema:alternateName GIP Arronax, 1, rue Arronax, 44187, Saint-Herblain cedex, France
174 schema:name GIP Arronax, 1, rue Arronax, 44187, Saint-Herblain cedex, France
175 Université de Nantes, Nantes, France
176 rdf:type schema:Organization
177 grid-institutes:grid.4817.a schema:alternateName Université de Nantes, Nantes, France
178 schema:name 6299 CNRS, Nantes, France
179 Centre de Recherche en Cancérologie Nantes/Angers (CRCNA), Nantes, France
180 Service de Médecine Nucléaire, CHU de Nantes, Nantes, France
181 Service de Médecine Nucléaire, Institut de Cancérologie de l’Ouest, Saint-Herblain, France
182 UMR892 Inserm, Nantes, France
183 Université de Nantes, Nantes, France
184 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...